# Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors

> **NCT06617169** · PHASE1 · RECRUITING · sponsor: **Monopar Therapeutics** · enrollment: 12 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Bladder Cancer
- Urothelial Carcinoma
- Triple-negative Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Gastric Cancer
- Ovarian Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** MNPR-101-PCTA-177Lu

## Key facts

- **NCT ID:** NCT06617169
- **Lead sponsor:** Monopar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-08
- **Primary completion:** 2026-12
- **Final completion:** 2027-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06617169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06617169, "Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06617169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*